D.A. Davidson & CO. Has $43.96 Million Stock Holdings in Pfizer Inc. (NYSE:PFE)

D.A. Davidson & CO. lifted its holdings in shares of Pfizer Inc. (NYSE:PFE) by 35.1% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,571,090 shares of the biopharmaceutical company’s stock after buying an additional 408,234 shares during the period. D.A. Davidson & CO.’s holdings in Pfizer were worth $43,959,000 at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. Clifford Swan Investment Counsel LLC boosted its stake in shares of Pfizer by 4.7% during the 4th quarter. Clifford Swan Investment Counsel LLC now owns 417,070 shares of the biopharmaceutical company’s stock worth $12,007,000 after buying an additional 18,611 shares during the last quarter. Cantor Fitzgerald Investment Advisors L.P. bought a new stake in shares of Pfizer in the 4th quarter valued at about $16,166,000. First Heartland Consultants Inc. raised its holdings in Pfizer by 43.3% in the 4th quarter. First Heartland Consultants Inc. now owns 13,013 shares of the biopharmaceutical company’s stock valued at $375,000 after acquiring an additional 3,933 shares during the period. ORG Partners LLC raised its holdings in Pfizer by 1,729.9% in the 2nd quarter. ORG Partners LLC now owns 47,028 shares of the biopharmaceutical company’s stock valued at $1,327,000 after acquiring an additional 44,458 shares during the period. Finally, Kempner Capital Management Inc. bought a new position in Pfizer in the 1st quarter valued at about $2,439,000. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Pfizer Price Performance

Shares of NYSE PFE traded up $0.29 during trading hours on Friday, hitting $29.01. 37,137,599 shares of the stock were exchanged, compared to its average volume of 26,838,326. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.60 and a current ratio of 0.86. The company has a market cap of $164.39 billion, a PE ratio of -483.42, a price-to-earnings-growth ratio of 1.02 and a beta of 0.69. The company’s fifty day simple moving average is $28.99 and its two-hundred day simple moving average is $28.01. Pfizer Inc. has a 1-year low of $25.20 and a 1-year high of $36.29.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, July 30th. The biopharmaceutical company reported $0.60 earnings per share for the quarter, beating analysts’ consensus estimates of $0.46 by $0.14. Pfizer had a negative net margin of 4.66% and a positive return on equity of 8.42%. The firm had revenue of $13.28 billion for the quarter, compared to analyst estimates of $12.96 billion. During the same quarter last year, the business posted $0.67 earnings per share. The company’s quarterly revenue was up 2.1% on a year-over-year basis. On average, sell-side analysts predict that Pfizer Inc. will post 2.66 EPS for the current year.

Pfizer Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 3rd. Shareholders of record on Friday, July 26th will be given a $0.42 dividend. The ex-dividend date of this dividend is Friday, July 26th. This represents a $1.68 dividend on an annualized basis and a yield of 5.79%. Pfizer’s dividend payout ratio is currently -2,799.53%.

Analysts Set New Price Targets

Several research analysts have weighed in on the stock. UBS Group increased their price target on shares of Pfizer from $30.00 to $31.00 and gave the company a “neutral” rating in a report on Wednesday, July 31st. Cantor Fitzgerald reissued an “overweight” rating and issued a $45.00 price target on shares of Pfizer in a report on Monday, August 19th. Daiwa America raised shares of Pfizer from a “moderate buy” rating to a “strong-buy” rating in a report on Wednesday, August 7th. Barclays increased their price target on shares of Pfizer from $30.00 to $32.00 and gave the company an “equal weight” rating in a report on Wednesday, July 31st. Finally, Wells Fargo & Company increased their target price on shares of Pfizer from $28.00 to $30.00 and gave the stock an “equal weight” rating in a research report on Wednesday, July 31st. Eight investment analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $34.54.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.